
**Scheme 2.6** Biota fusion inhibitors.**Scheme 2.7** Wyeth fusion inhibitor RFI-641 (**25**).

discontinued, citing safety concerns in press releases, and the licensing rights were returned to Biota. Biota intends to pursue a series of back-up compounds (according to a press release on 10 August 2009).⁶²

2.5.5 RFI-641

Wyeth developed a polyanionic compound that was shown to be an RSV fusion inhibitor but also had some activity against herpes virus (see **25**, Scheme 2.7).^{63,64} Intranasal delivery of **25** was efficacious in the RSV murine model and also in the African green monkey. A 2log₁₀ viral load drop was observed in BAL samples in the high-dose arm (2 h inhalation *versus* 15 min); no statistical difference was seen in nasal washed and throat swap titers.⁶⁵ This compound progressed into Phase 2 studies, but development was halted.